United States - English - NLM (National Library of Medicine)

physicians total care, inc. - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - ditropan xl® (oxybutynin chloride) is a once-daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ditropan xl® is also indicated in the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ditropan xl® (oxybutynin chloride) is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. ditropan xl® is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.

United States - English - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - ditropan xl ® (oxybutynin chloride) is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ditropan xl ® is also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ditropan xl ® is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma. ditropan xl ® is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. there have been reports of hypersensitivity reactions, including anaphylaxis and angioedema. risk summary there are no adequate data on ditropan xl ® use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscar

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxybutynin hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; brilliant blue fcf aluminium lake; lactose; calcium stearate - treatment of detrusor over-activity where conservative measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxybutynin hydrochloride -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmaco distribution (pty) ltd - tablet - see ingredients - each tablet contains oxybutynin chloride 5 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - oxybutynin hydrochloride - tablet - 2.5 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - oxybutynin hydrochloride - tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - oxybutynin hydrochloride - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - oxybutynin hydrochloride - oral tablet - 5mg

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - oxybutynin hydrochloride - tablet - oxybutynin hydrochloride 5 mg - urologicals